Micro Developing Active

Eli Lilly erweitert Zepbound-Zugang für langfristiges Wachstum

Score
0,5
Dynamik
▲ 0,0
Artikel
9
Quellen
4

Zusammenfassung

Ein Artikel gehört zu dieser Erzählung, wenn er die Ausweitung des Zugangs zu Zepbound durch Eli Lilly und dessen langfristigen Wachstumsausblick behandelt.

Verwandte Artikel

Jim Cramer Likes Eli Lilly’s (LLY) New Deal

Yahoo Finance · Apr 05, 2026
Mixed

Eli Lilly's One-Two Punch Could Knock Novo Nordisk Out of the Obesity Drug Fight

Nasdaq · Apr 04, 2026
Mixed

Eli Lilly secures long-awaited FDA approval for its obesity pill. Here's what to know

CNBC · Apr 01, 2026
Mixed

The cutthroat battle for the US weight-loss drug market

BBC Business · Mär 23, 2026
Mixed

Eli Lilly and Company (LLY) Expands Zepbound Access as Pricing Reforms Boost Long-Term Growth Outlook

Yahoo Finance · Mär 22, 2026
Mixed

Quellen

Eli Lilly's One-Two Punch Could Knock Novo Nordisk Out of … Nasdaq
Jim Cramer Likes Eli Lilly’s (LLY) New Deal Yahoo Finance
Is Eli Lilly and Company (LLY) The Best Pharma Stock … Yahoo Finance
Eli Lilly secures long-awaited FDA approval for its obesity pill. … CNBC
Eli Lilly reaches $2.75 billion deal with Insilico to bring … CNBC
Here's How Much Upside Eli Lilly Stock Has, According to … Yahoo Finance
The cutthroat battle for the US weight-loss drug market BBC Business
Eli Lilly and Company (LLY) Expands Zepbound Access as Pricing … Yahoo Finance

Zeitverlauf

Zuletzt aktualisiert Mär 22, 2026